IPO Boutique

Conatus Pharmaceuticals IPO Advisory

Share this IPO Profile:

Smart Search
Company begins with...
Company contains...

For IPO Boutique's "scale of 1 to 5" BUY rating on Conatus Pharmaceuticals, and our comprehensive analysis, click "Buy Market Research".
Company
Symbol
Price Range
Issue Price
Open
Shares
Trade Date
Conatus PharmaceuticalsCNAT -
NASDAQ
$10.00-$12.00 $11.00 $11.006 million7/25/2013
Stifel Nicolaus Weisel, Piper Jaffray
Co-Manager(s):
JMP Securities, SunTrust Robinson Humphrey
Health Care
Filing(s):

Filed 2013-06-13



Conatus Pharmaceuticals Quote & Chart - Click for current quote - CNAT

About Conatus Pharmaceuticals (adapted from Conatus Pharmaceuticals prospectus):
They are a biotechnology company focused on the development and commercialization of novel medicines to treat liver disease.

This description is adapted from prospectus. This description is not intended to be a recommendation to buy stock from this company. To see the company's full description, view their prospectus.



IPO Boutique aggregates information on public companies and private companies, such as "CNAT" IPO, which is intended to educate our readers and help them evaluate potential investment opportunities and market conditions. We endeavor to research the financial industry and obtain independent verification of factual statements before presenting them to our users. Be informed.

Used our Comprehensive Single Promo Advisory and want more?
We also offer a monthly or annual subscription






© 2005 - 2024 IPO Boutique. All Rights Reserved